Debt-to-equity of Amylyx Pharmaceuticals, Inc. from 30 Sep 2022 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Amylyx Pharmaceuticals, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2022 to 30 Sep 2025.
  • Amylyx Pharmaceuticals, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 12%, a 51% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Amylyx Pharmaceuticals, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 12% -13% -51% 30 Sep 2025
Q2 2025 18% -3% -15% 30 Jun 2025
Q1 2025 21% +2% +12% 31 Mar 2025
Q4 2024 26% +10% +63% 31 Dec 2024
Q3 2024 25% +10% +68% 30 Sep 2024
Q2 2024 21% +3% +20% 30 Jun 2024
Q1 2024 19% +2% +9.5% 31 Mar 2024
Q4 2023 16% -1% -4.6% 31 Dec 2023
Q3 2023 15% -14% -48% 30 Sep 2023
Q2 2023 17% 30 Jun 2023
Q1 2023 17% 31 Mar 2023
Q4 2022 17% 31 Dec 2022
Q3 2022 28% 30 Sep 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.